Artal Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Artal Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,779,708	Closed	-$3.35M	–	125
2017 Q4	$3.35M	Buy	1,779,708 +314,325	+21%	+$686K	0.05%	79
2017 Q3	$3.64M	Hold	1,465,383	–	–	0.06%	74
2017 Q2	$4.04M	Hold	1,465,383	–	–	0.07%	73
2017 Q1	$4.42M	Hold	1,465,383	–	–	0.1%	64
2016 Q4	$4.63M	Hold	1,465,383	–	–	0.1%	54
2016 Q3	$5M	Hold	1,465,383	–	–	0.1%	56
2016 Q2	$3.35M	Hold	1,465,383	–	–	0.07%	52
2016 Q1	$3.68M	Sell	1,465,383 -123,092	-8%	-$275K	0.07%	45
2015 Q4	$5.26M	Hold	1,588,475	–	–	0.1%	64
2015 Q3	$3.85M	Hold	1,588,475	–	–	0.09%	62
2015 Q2	$4.65M	Hold	1,588,475	–	–	0.2%	56
2015 Q1	$6.37M	Hold	1,588,475	–	–	0.29%	52
2014 Q4	$4.78M	Buy	+1,588,475	New	+$4.3M	0.17%	67

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's LCTX Position: Q1 2018 in Review

Artal Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2018, closing a stake of 1,779,708 shares — an estimated $3.35M sold.

Artal Group first reported a position in LCTX in Q4 2014 and held it in 13 quarters. The position peaked at $6.37M in Q1 2015. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2018.

Artal Group reported no remaining Lineage Cell Therapeutics position as of Q1 2018 after selling out during the quarter.
Artal Group sold 1,779,708 Lineage Cell Therapeutics shares in Q1 2018, an estimated $3.35M.
Artal Group first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 13 quarters.
Artal Group's Lineage Cell Therapeutics position peaked at $6.37M in Q1 2015.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.